Evidence map›Paper›PMID 34880463›Full record

ArticleNature biotechnology2021

iGEM comes of age: trends in its research output.

Ashwin K Jainarayanan, Anastasios Galanis, Athira Sreejith, Sourav Suresh, Amatullah Mustafa Nakara, Guilherme E Kundlatsch, Roger Rubio-Sánchez

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ashwin K JainarayananAcademia & Research Committee, After iGEM Team, iGEM Foundation, Cambridge, MA, USA. ashwin.jainarayanan@exeter.ox.ac.uk.ORCID http://orcid.org/0000-0003-3523-1477
Anastasios GalanisAcademia & Research Committee, After iGEM Team, iGEM Foundation, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-8118-5355
Athira SreejithAcademia & Research Committee, After iGEM Team, iGEM Foundation, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7974-4509
Sourav SureshAcademia & Research Committee, After iGEM Team, iGEM Foundation, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-8595-8677
Amatullah Mustafa NakaraAcademia & Research Committee, After iGEM Team, iGEM Foundation, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4004-465X
Guilherme E KundlatschAcademia & Research Committee, After iGEM Team, iGEM Foundation, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7730-8386
Roger Rubio-SánchezAcademia & Research Committee, After iGEM Team, iGEM Foundation, Cambridge, MA, USA. rmr44@cam.ac.uk.ORCID http://orcid.org/0000-0001-5574-5809

Funding

RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/M011224/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34880463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.